Target Interacting Protein Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T82254 | Target Info | |||
Target Name | Apoptosis regulator BAK (BAK) | ||||
Synonyms | CDN1; Bcl2like protein 7; Bcl2L7; Bcl2-L-7; Bcl2 homologous antagonist/killer; Bcl-2-like protein 7; Bcl-2 homologous antagonist/killer | ||||
Target Type | Literature-reported Target | ||||
Gene Name | BAK1 | ||||
Biochemical Class | B-cell lymphoma Bcl-2 | ||||
UniProt ID |
Target Interacting Proteins | Top | ||||
---|---|---|---|---|---|
Alpha-type channels | [+] 1 Alpha-type channels | + | |||
Interacting Target Name | Apoptosis regulator Bcl-xL (BCL-xL) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Bcl-XL; BCLX; Bcl-2-like protein 1; Bcl2like protein 1; Bcl2-L-1; Bcl2L1; BCL2L; Apoptosis regulator Bcl-X | ||||
Evidence Score (E-score) | 8 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [1] | |||
2 | Affinity Capture-Western | [2] | |||
3 | Affinity Capture-Western | [3] | |||
4 | Fluorescence Resonance Energy Transfer | [4] | |||
5 | Protein-peptide | [5] | |||
6 | Reconstituted Complex | [6] | |||
7 | Yeast two hybrid | [7] | |||
8 | Yeast two hybrid | [2] | |||
Auxiliary transporters | [+] 2 Auxiliary transporters | + | |||
Interacting Target Name | Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | mcl1/EAT; Induced myeloid leukemia cell differentiation protein Mcl-1; Bcl-2-related protein EAT/mcl1; Bcl-2-like protein 3; Bcl2-L-3; BCL2L3 | ||||
Evidence Score (E-score) | 6 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [8] | |||
2 | Affinity Capture-Western | [9] | |||
3 | Affinity Capture-Western | [3] | |||
4 | Protein-peptide | [10] | |||
5 | Reconstituted Complex | [11] | |||
6 | Yeast two hybrid | [12] | |||
Interacting Target Name | Apoptosis regulator Bcl-2 (BCL-2) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Bcl-2; Apoptosis regulator Bcl-2 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [13] | |||
2 | Protein-peptide | [14] | |||
Pore-forming toxins | [+] 1 Pore-forming toxins | + | |||
Interacting Target Name | Cellular tumor antigen p53 (TP53) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Tumor suppressor p53; Phosphoprotein p53; P53; Antigen NY-CO-13 | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [11] | |||
2 | Affinity Capture-Western | [11] | |||
3 | Co-fractionation | [15] | |||
4 | Reconstituted Complex | [11] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol. 1999 Mar 8;144(5):903-14. | ||||
REF 2 | Towards a proteome-scale map of the human protein-protein interaction network. Nature. 2005 Oct 20;437(7062):1173-8. | ||||
REF 3 | Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis. Biochem Pharmacol. 2011 Jan 1;81(1):32-42. | ||||
REF 4 | High-throughput methods to detect dimerization of Bcl-2 family proteins. Anal Biochem. 2003 Nov 15;322(2):170-8. | ||||
REF 5 | Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal Biochem. 2002 Aug 1;307(1):70-5. | ||||
REF 6 | Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001 Feb;3(2):173-82. | ||||
REF 7 | An empirical framework for binary interactome mapping. Nat Methods. 2009 Jan;6(1):83-90. | ||||
REF 8 | Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509. | ||||
REF 9 | Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov;10(5):375-88. | ||||
REF 10 | Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005 Jun 1;19(11):1294-305. | ||||
REF 11 | Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 2004 May;6(5):443-50. | ||||
REF 12 | MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem. 2000 Aug 18;275(33):25255-61. | ||||
REF 13 | Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004 Feb 20;116(4):527-40. | ||||
REF 14 | Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24. | ||||
REF 15 | Resveratrol induces p53-independent, X-linked inhibitor of apoptosis protein (XIAP)-mediated Bax protein oligomerization on mitochondria to initiate cytochrome c release and caspase activation. J Biol Chem. 2011 Aug 19;286(33):28749-60. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.